Biocomposites and methods of making the same
View Patent ↗In general, the present invention is related to biopolymer and biocomposite materials and structures, and methods of making and using the same. In some embodiments, the present invention is directed to oriented collagen based biocomposite materials and structures, and methods of making.
1. A method of making oriented fibrillar biopolymer material comprising the steps of:
preparing a collagen solution or gel of a lyotropic liquid crystal phase;
flowing the collagen solution or gel in a substantially laminar flow regime or manner; and
transforming the collagen solution or gel from a liquid to solid phase to form an oriented fibrillar biopolymer material.
2. The method according to claim 1 wherein the fibrillar biopolymer solution or gel is prepared by adjusting one or more of: the concentration, temperature, pH, ionic strength, or additives.
3. The method according to claim 1 wherein the step of flowing results in formation of a particular pattern with long range orientational order.
4. The method according to claim 1 wherein the step of transforming further comprises promoting self assembly of the fibrillar biopolymer.
5. The method according to claim 1 wherein the step of transforming further comprises changing ambient conditions during transformation.
6. The method according to the claim 5 where the ambient conditions are any one of more of: the ambient humidity, temperature, or electrostatic condition.
7. The method according to the claim 1 wherein the fibrillar biopolymer solution or gel exhibits ionic strength and pH, which may be adjusted by means of external evaporation.
8. The method according to the claim 1 wherein the liquid phase is deposited on a functionalized substrate.
9. The method according to the claim 8 wherein functionalization is configured to promote low adhesion to the substrate.
10. The method according to the claim 8 wherein functionalization is configured to promote high adhesion to the substrate.
11. The method according to the claim 8 wherein functionalization is configured to influence the final orientation in the solid phase.
12. The method according to the claim 1 where the oriented fibrillar material is further cross-linked and sterilized.
13. The method according to the claim 1 where oriented fibrillar material is removed from the substrate with low adhesion.
14. The method according to the claim 13 where the oriented fibrillar material has the form of ribbon.
15. The method according to the claim 1 wherein the phase is a lyotropic liquid crystal phase.
16. The method according to claim 1 further comprising the steps of:
dipping the oriented biopolymer material into a solution; and
pulling the oriented biopolymer material from the solution such that the material collapses into a pseudo-fiber at the air-liquid interface to form a fibrillar biopolymer pseudo-fiber.
17. The method according to claim 16 further comprising drying the fibrillar biopolymer pseudo-fiber.
18. The method according to claim 16 further comprising cross-linking the fibrillar biopolymer pseudo-fiber.
19. The method according to claim 16 wherein the oriented biopolymer material is comprised of one or more ribbons.
20. The method according to claim 16 wherein the solution has a neutral pH.
21. The method according to claim 16 wherein the solution has a pH in the range of 2 to 9.
22. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed having a layer with average fibril orientation in any direction parallel to the layer.
23. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed having a layer with average fibril orientation in the direction perpendicular to the layer.
24. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed having a tube with average fibril orientation having an angle with an axis of the tube.
25. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed having single crimp pattern.
26. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed having double crimp pattern with an arbitrary angle between crimp formations.
27. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed having a crimp pattern formed by left-handed and right-handed helical fibrils.
28. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed having a crimp pattern in the form of a chevron of substantially parallel lines at substantially equal alternating angles.
29. The method according to claim 1 further comprising:
forming a biocomposite structure comprising at least one of the oriented fibrillar biopolymer material and a biodegradable biocompatible matrix.
30. The method according to claim 1 further comprising:
forming a biocomposite structure comprising a plurality of the oriented fibrillar biopolymer materials with arbitrary orientations and a biodegradable biocompatible matrix; and
bonding together said plurality of fibrillar biopolymer materials.
31. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed for use as a matrix and substrate in cell and tissue culture applications.
32. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed for use as an in vivo cell guiding scaffold.
33. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed to deliver components of platelet rich plasma.
34. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed to deliver live cells for tissue repair and regeneration.
35. The method according to claim 16 wherein the fibrillar biopolymer pseudo-fiber or plurality of pseudo-fibers are formed to deliver live cells and components of platelet rich plasma for tissue repair and regeneration.
36. The method according to claim 1 wherein the oriented fibrillar biopolymer material is formed to deliver peptides, drugs, growth factors, and small molecules.
37. The method according to claim 29 wherein the biocompatible matrix consists of glycosaminoglycans, proteoglycans, vanadate, calcium phosphates, live cells, growth factors, and their combinations.